LPC
DMAAR

Lineage Point Capital’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Lineage Point Capital’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.5K Hold
50,000
– – ﹤0.01% 362
2026
Q1 		$3.02K Buy
+50,000
New +$5.29K ﹤0.01% 269

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Lineage Point Capital's DMAAR Position: Q2 2026 in Review

Lineage Point Capital held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 50,000 shares worth $5.5K. The position accounts for ﹤0.01% of the portfolio, ranked #362.

Lineage Point Capital first reported a position in DMAAR in Q1 2026 and has held it in 2 quarters since. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Lineage Point Capital held 50,000 shares of Drugs Made In America Acquisition Corp Rights worth $5.5K as of Q2 2026.
  • Lineage Point Capital left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Lineage Point Capital's portfolio in Q2 2026, its #362 holding.
  • Lineage Point Capital first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2026 and has held it in 2 quarters since.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Lineage Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.